Feng Chi Biotech Corp. (TPEX:6744)
Taiwan · Delayed Price · Currency is TWD 14.00
0.00 (0.00%)
Aug 18, 2026, 11:17 AM CST
Feng Chi Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 156.99 | 177.36 | 171.1 | 180.58 | 193.46 | 182.57 | |
Revenue Growth | -12.75% | 3.66% | -5.25% | -6.66% | 5.96% | 2.05% |
Cost of Revenue | 86.54 | 98.2 | 93.95 | 99.86 | 110.02 | 96.46 |
Gross Profit | 70.45 | 79.16 | 77.15 | 80.72 | 83.44 | 86.11 |
Selling, General & Admin | 50.99 | 51.81 | 46.43 | 43.46 | 44.29 | 45.48 |
Research & Development | 12.32 | 13.5 | 14.6 | 13.1 | 12.09 | 14.19 |
Operating Expenses | 63.31 | 65.31 | 61.03 | 56.56 | 56.38 | 59.67 |
Operating Income | 7.14 | 13.85 | 16.12 | 24.16 | 27.07 | 26.44 |
Interest Expense | -0.14 | -0.18 | -0.25 | -0.33 | -0.06 | -0.1 |
Interest & Investment Income | 2.8 | 3 | 3.24 | 3.09 | 1.88 | 1.38 |
Currency Exchange Gain (Loss) | 0.04 | 0.04 | 0.68 | 0.34 | 1.5 | 0.01 |
Other Non Operating Income (Expenses) | 1.46 | 0.23 | 0.54 | 0.03 | 0.03 | 0.13 |
EBT Excluding Unusual Items | 11.3 | 16.93 | 20.33 | 27.3 | 30.42 | 27.86 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.2 |
Pretax Income | 11.3 | 16.93 | 20.33 | 27.3 | 30.42 | 28.06 |
Income Tax Expense | 1.39 | 2.46 | 3.74 | 4.51 | 5.81 | 4.92 |
Net Income | 9.91 | 14.47 | 16.59 | 22.79 | 24.61 | 23.14 |
Net Income to Common | 9.91 | 14.47 | 16.59 | 22.79 | 24.61 | 23.14 |
Net Income Growth | -36.66% | -12.78% | -27.19% | -7.40% | 6.39% | -8.89% |
Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | 15 |
Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | 15 |
Shares Change | -1.05% | -0.08% | 0.02% | -0.07% | 0.08% | 0.01% |
EPS (Basic) | 0.65 | 0.94 | 1.08 | 1.48 | 1.60 | 1.50 |
EPS (Diluted) | 0.65 | 0.94 | 1.07 | 1.47 | 1.60 | 1.50 |
EPS Growth | -35.79% | -12.16% | -27.21% | -8.03% | 6.55% | -8.54% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 1.72 | -9.79 | 10.46 | 14.02 | 28.4 | 31.83 |
Free Cash Flow Per Share | 0.11 | -0.63 | 0.68 | 0.91 | 1.84 | 2.06 |
Dividend Per Share | - | - | 0.950 | 1.050 | 1.350 | 1.250 |
Dividend Growth | - | - | -9.52% | -22.22% | 8.00% | 8.70% |
Gross Margin | 44.87% | 44.63% | 45.09% | 44.70% | 43.13% | 47.16% |
Operating Margin | 4.55% | 7.81% | 9.42% | 13.38% | 13.99% | 14.48% |
Profit Margin | 6.31% | 8.16% | 9.70% | 12.62% | 12.72% | 12.67% |
Free Cash Flow Margin | 1.10% | -5.52% | 6.11% | 7.76% | 14.68% | 17.43% |
EBITDA | 16.98 | 23.25 | 22.62 | 28.66 | 30.67 | 32.53 |
EBITDA Margin | 10.82% | 13.11% | 13.22% | 15.87% | 15.85% | 17.82% |
D&A For EBITDA | 9.85 | 9.41 | 6.5 | 4.5 | 3.6 | 6.09 |
EBIT | 7.14 | 13.85 | 16.12 | 24.16 | 27.07 | 26.44 |
EBIT Margin | 4.55% | 7.81% | 9.42% | 13.38% | 13.99% | 14.48% |
Effective Tax Rate | 12.32% | 14.52% | 18.39% | 16.51% | 19.08% | 17.55% |